Diagnosis and management of parathyroid cancer

Nature Reviews Endocrinology

Volumn 8, Issue 10, 2012, Pages 612-622

  Schulte, Klaus Martin ^a   Talat, Nadia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; MICRORNA; PARATHYROID HORMONE;

BONE INJURY; BONE METASTASIS; CALCIUM BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CDC73 GENE; CLINICAL FEATURE; DISTANT METASTASIS; ENDOCRINE SURGERY; EXTERNAL BEAM RADIOTHERAPY; FAMILY HISTORY; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SCREENING; GERM LINE; HEALTH CARE COST; HETEROZYGOTE; HIGH RISK PATIENT; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HYPERCALCEMIA; LUNG METASTASIS; MEDIASTINUM METASTASIS; NECK TUMOR; ONCOGENE; PARATHYROID ADENOMA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID TUMOR; PREOPERATIVE EVALUATION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THYROID CANCER; TUMOR BIOPSY; TUMOR CELL; ULTRASOUND;

CALCIUM; GERM-LINE MUTATION; HUMANS; MUTATION; PARATHYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84866620563     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.102     Document Type: Review

References (126)

1. Rodgers, S. E. & Perrier, N. D. Parathyroid carcinoma. Curr. Opin. Oncol. 18, 16-22 (2006). (Pubitemid 43740445)
2. Koea, J. B. & Shaw, J. H. Parathyroid cancer: biology and management. Surg. Oncol. 8, 155-165 (1999).
3. Talat, N. & Schulte, K. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann. Surg. Oncol. 17, 2156-2174 (2010).
4. Kulkarni, P. S. & Parikh, P. M. The carcinoma of parathyroid gland. Indian J. Cancer 41, 51-59 (2004). (Pubitemid 39164003)
5. Perrier, N. D. The parathyroid glands: what the endocrine surgeon should know. Endocr. Pract. 17 (Suppl. 1), 1 (2011).
6. Sharretts, J. M., Kebebew, E. & Simonds, W. F. Parathyroid cancer. Semin. Oncol. 37, 580-590 (2010).
7. Marcocci, C. et al. Parathyroid carcinoma. J. Bone Miner. Res. 23, 1869-1880 (2008).
8. DeLellis, R. A. Parathyroid tumors and related disorders. Mod. Pathol. 24 (Suppl. 2), S78-S93 (2011).
9. Sharretts, J. M. & Simonds, W. F. Clinical and molecular genetics of parathyroid neoplasms. Best Pract. Res. Clin. Endocrinol. Metab. 24, 491-502 (2010).
10. Fang, S. H. & Lal, G. Parathyroid cancer. Endocr. Pract. 17 (Suppl. 1), 36-43 (2011).
11. Snell, S. B., Gaar, E. E., Stevens, S. P. & Flynn, M. B. Parathyroid cancer, a continued diagnostic and therapeutic dilemma: report of four cases and review of the literature. Am. Surg. 69, 711-716 (2003).
12. Lee, Y. S. et al. Parathyroid carcinoma: a 16-year experience in a single institution. Endocr. J. 57, 493-497 (2010).
13. Spiegel, A. M. & Libutti, S. K. Future diagnostic and therapeutic trends in endocrine cancers. Semin. Oncol. 37, 691-695 (2010).
14. Schulte, K. M. et al. Classification of parathyroid cancer. Ann. Surg. Oncol. http://dx.doi.org/10.1245/s10434-012-2306-6.
15. Schulte, K. M. et al. Lymph node involvement and surgical approach in parathyroid cancer. World J. Surg. 34, 2611-2620 (2010).
16. DeLellis, R. A., Mazzaglia, P. & Mangray, S. Primary hyperparathyroidism: a current perspective. Arch. Pathol. Lab. Med. 132, 1251-1262 (2008).
17. Adam M. A., Untch, B. R. & Olson, J. A. Jr. Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics. Oncologist 15, 61-72 (2010).
18. Cavalier, E. et al. The ratio of parathyroid hormone as measured by third-and second-generation assays as a marker for parathyroid carcinoma. J. Clin. Endocrinol. Metab. 95, 3745-3749 (2010).
19. Caron, P. et al. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 70, 533-538 (2009).
20. Rubin, M. R. et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH1-84 is overproduced in parathyroid carcinoma. Clin. Chem. 53, 1470-1476 (2007). (Pubitemid 47206343)
21. Sidhu, P. S., Talat, N., Patel, P., Mulholland, N. J. & Schulte, K. M. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur. Radiol. 21, 1865-1873 (2011).
22. Newey, P. J., Bowl, M. R., Cranston, T. & Thakker, R. V. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism- jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum. Mutat. 31, 295-307 (2010).
23. Fallah, M., Kharazmi, E., Sundquist, J. & Hemminki, K. Nonendocrine cancers associated with benign and malignant parathyroid tumors. J. Clin. Endocrinol. Metab. 96, E1108-E1114 (2011).
24. Hundahl, S. A., Fleming, I. D., Fremgen, A. M. & Menck, H. R. Two hundred eighty-six cases of parathyroid carcinoma treated in the U. S. between 1985-1995: a National Cancer Data Base report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86, 538-544 (1999). (Pubitemid 29347419)
25. Lee, P. K., Jarosek, S. L., Virnig, B. A., Evasovich, M. & Tuttle, T. M. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109, 1736-1741 (2007). (Pubitemid 46668534)
26. Bondeson, L., Grimelius, L. & Delellis, R. A. World Health Organisation Classification of Tumours, Pathology and Genetics: Tumour of Endocrine Organs (IARC, Lyon, 2004).
27. DeLellis, R. A. Parathyroid carcinoma - an overview. Adv. Anat. Pathol. 12, 53-61 (2005).
28. Carlson, D. Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Arch. Pathol. Lab. Med. 134, 1639-1644 (2010).
29. Goldfarb, M. et al. Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism. Endocr. Pract. 15, 463-468 (2009).
30. Chaychi, L., Belbruno, K., Golding, A. & Memoli, V. Unusual manifestation of parathyroid carcinoma in the setting of papillary thyroid cancer. Endocr. Pract. 16, 664-668 (2010).
31. Obara, T. et al. Flow cytometric DNA analysis of parathyroid tumors with special reference to its diagnostic and prognostic value in parathyroid carcinoma. Cancer 65, 1789-1793 (1990). (Pubitemid 20116651)
32. Montenegro, F. L. et al. Clinical suspicion and parathyroid carcinoma management. Sao Paulo Med. J. 124, 42-44 (2006).
33. Robert, J. H. et al. Primary hyperparathyroidism: can parathyroid carcinoma be anticipated on clinical and biochemical grounds? Report of nine cases and review of the literature. Ann. Surg. Oncol. 12, 526-532 (2005). (Pubitemid 40898034)
34. Agarwal, G. et al. Indian primary hyperparathyroidism patients with parathyroid carcinoma do not differ in clinicoinvestigative characteristics from those with benign parathyroid pathology. World J. Surg. 30, 732-742 (2006). (Pubitemid 43724100)
35. Favia, G., Lumachi, F., Polistina, F. & D'Amico, D. F. Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J. Surg. 22, 1225-1230 (1998). (Pubitemid 28514341)
36. Cheung, K., Wang, T. S., Farrokhyar, F., Roman, S. A. & Sosa, J. A. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann. Surg. Oncol. 19, 577-583 (2012).
37. Lee, L. & Steward, D. L. Techniques for parathyroid localization with ultrasound. Otolaryngol. Clin. North Am. 43, 1229-1239 (2011).
38. Obara, T. & Fujimoto, Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J. Surg. 15, 738-744 (1991).
39. Ruda, J. M., Hollenbeak, C. S. & Stack, B. C. Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol. Head Neck Surg. 132, 359-372 (2005). (Pubitemid 40326684)
40. Lepage, R. et al. A non-1-84 circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin. Chem. 44, 805-809 (1998). (Pubitemid 28176023)
41. John, M. R. et al. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J. Clin. Endocrinol. Metab. 84, 4287-4290 (1999). (Pubitemid 30644232)
42. D'Amour, P. et al. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH1-84 is overproduced in primary and secondary hyperparathyroidism. Clin. Chem. 49, 2037-2044 (2003). (Pubitemid 37449476)
43. Caron, P. et al. Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation. Clin. Endocrinol. (Oxf.) 74, 694-698 (2011).
44. Fernandez-Ranvier, G. G. et al. Nonfunctioning parathyroid carcinoma: case report and review of literature. Endocr. Pract. 13, 750-757 (2007).
45. Wilkins, B. J. & Lewis, J. S. Jr. Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol. 3, 140-149 (2009).
46. Ruda, J. M., Stack, B. C. Jr & Hollenbeak, C. S. The cost-effectiveness of additional preoperative ultrasonography or sestamibi-SPECT in patients with primary hyperparathyroidism and negative findings on sestamibi scans. Arch. Otolaryngol. Head Neck Surg. 132, 46-53 (2006). (Pubitemid 43127963)
47. Weber, A. L., Randolph, G. & Aksoy, F. G. The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings. Radiol. Clin. North Am. 38, 1105-1129 (2000).
48. Fakhran, S., Branstetter, B. F. T. & Pryma, D. A. Parathyroid imaging. Neuroimaging Clin. North Am. 18, 537-549 (2008). (Pubitemid 352004239)
49. Cho, N. L., Gawande, A. A., Sheu, E. G., Moore, F. D. Jr & Ruan, D. T. Critical role of identification of the second gland during unilateral parathyroid surgery: a prospective review of 119 patients with concordant localization. Arch. Surg. 146, 512-516 (2011).
50. Vazquez, B. J. & Richards, M. L. Imaging of the thyroid and parathyroid glands. Surg. Clin. North Am. 91, 15-32 (2011).
51. Mulla, M. & Schulte, K. M. Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment. Clin. Endocrinol. (Oxf.) 76, 131-136 (2012).
52. Prommegger, R. et al. Virtual neck exploration: a new method for localizing abnormal parathyroid glands. Ann. Surg. 250, 761-765 (2009).
53. Levine, D. S. & Wiseman, S. M. Fusion imaging for parathyroid localization in primary hyperparathyroidism. Expert Rev. Anticancer Ther. 10, 353-363 (2010).
54. Gardner, C. J. et al. Localization of metastatic parathyroid carcinoma by 18F FDG PET scanning. J. Clin. Endocrinol. Metab. 95, 4844-4845 (2010).
55. Evangelista, L. et al. FDG-PET/CT and parathyroid carcinoma: review of literature and illustrative case series. World J. Clin. Oncol. 2, 348-354 (2011).
56. Sundin, A. et al. PET and parathyroid l-11C-methionine accumulation in hyperparathyroidism. J. Nucl. Med. 37, 1766-1770 (1996). (Pubitemid 26378358)
57. Delellis, R. A. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma. Endocr. Pathol. 19, 221-225 (2008).
58. Lim, S., Elston, M. S., Gill, A. J., Marsh, D. J. & Conaglen, J. V. Metastatic parathyroid carcinoma initially misdiagnosed as parathyroid adenoma: the role of parafibromin in increasing diagnostic accuracy. Intern. Med. J. 41, 695-699 (2011).
59. Sarquis, M. S. et al. Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 143, 630-640 (2008).
60. Juhlin, C. C. & Hoog, A. Parafibromin as a diagnostic instrument for parathyroid carcinoma - lone ranger or part of the posse? Int. J. Endocrinol. 2010, 324964 (2010).
61. Morrison, C. et al. Molecular classification of parathyroid neoplasia by gene expression profiling. Am. J. Pathol. 165, 565-576 (2004). (Pubitemid 38971386)
62. Valdivielso, P., Lopez-Sanchez, J., Garrido, A. & Sanchez-Carrillo, J. J. Metastatic calcifications and severe hypercalcemia in a patient with parathyroid carcinoma. J. Endocrinol. Invest. 29, 641-644 (2006). (Pubitemid 44446275)
63. Erickson, L. A. et al. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am. J. Surg. Pathol. 23, 288-295 (1999). (Pubitemid 29117564)
64. Costa-Guda, J., Marinoni, I., Molatore, S., Pellegata, N. S. & Arnold, A. Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 96, E701-E706 (2011).
65. Giusti, L. et al. A proteomic approach to study parathyroid glands. Mol. Biosyst. 7, 687-699 (2011).
66. Dossat, N. et al. Comparison of supervised classification methods for protein profiling in cancer diagnosis. Cancer Inform. 3, 295-305 (2007).
67. Juhlin, C. C. et al. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr. Pathol. 21, 166-177 (2010).
68. Haven, C. J. et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 64, 7405-7411 (2004). (Pubitemid 39372081)
69. Corbetta, S. et al. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr. Relat. Cancer 17, 135-146 (2010).
70. Rahbari, R. et al. Identification of differentially expressed microRNA in parathyroid tumors. Ann. Surg. Oncol. 18, 1158-1165 (2011).
71. Spinelli, C., Bonadio, A. G., Berti, P., Materazzi, G. & Miccoli, P. Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J. Endocrinol. Invest. 23, 255-257 (2000). (Pubitemid 30311374)
72. Westin, G., Bjorklund, P. & Akerstrom, G. Molecular genetics of parathyroid disease. World J. Surg. 33, 2224-2233 (2009).
73. Uchino, S. et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res. 60, 5553-5557 (2000).
74. Piecha, G., Chudek, J. & Wiecek, A. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Int. J. Endocrinol. 2010, 928383 (2011).
75. Thakker, R. V. Multiple endocrine neoplasia type 1 (MEN1). Best Pract. Res. Clin. Endocrinol. Metab. 24, 355-370 (2010).
76. Marsh, D. J. & Gimm, O. Multiple endocrine neoplasia: types 1 and 2. Adv. Otorhinolaryngol. 70, 84-90 (2011).
77. Brandi, M. L., Marx, S. J., Aurbach, G. D. & Fitzpatrick, L. A. Familial multiple endocrine neoplasia type I: a new look at pathophysiology. Endocr. Rev. 8, 391-405 (1987).
78. Shih, R. Y. et al. Parathyroid carcinoma in multiple endocrine neoplasia type 1 with a classic germline mutation. Endocr. Pract. 15, 567-572 (2009).
79. Davenport, C. & Agha, A. The role of menin in parathyroid tumorigenesis. Adv. Exp. Med. Biol. 668, 79-86 (2009).
80. Marx, S. J. et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J. Bone Miner. Res. 17 (Suppl. 2), N37-N43 (2002). (Pubitemid 35222311)
81. Bradley, K. J. et al. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J. Intern. Med. 257, 18-26 (2005). (Pubitemid 40129123)
82. Bradley, K. J. & Thakker, R. V. The hyperparathyroidism-jaw tumour (HPT-JT) syndrome. Clin. Cases Miner. Bone Res. 3, 167-174 (2006). (Pubitemid 44859639)
83. Hannan, F. M. et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat. Clin. Pract. Endocrinol. Metab. 4, 53-58 (2008). (Pubitemid 350291116)
84. Carpten, J. D. et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 32, 676-680 (2002). (Pubitemid 35435184)
85. Rozenblatt-Rosen, O. et al. The parafibromin tumor suppressor protein is part of a human PAF1 complex. Mol. Cell Biol. 25, 612-620 (2005). (Pubitemid 40096583)
86. Yart, A. et al. The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol. Cell Biol. 25, 5052-5060 (2005). (Pubitemid 40781105)
87. Lin, L., Zhang, J. H., Panicker, L. M. & Simonds, W. F. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc. Natl Acad. Sci. USA 105, 17420-17425 (2008).
88. Woodard, G. E. et al. Parafibromin, product of the hyperparathyroidism- jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24, 1272-1276 (2005). (Pubitemid 40313928)
89. Cascon, A. et al. Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family. Genes Chromosomes Cancer 50, 922-929 (2011).
90. Hahn, M. A. et al. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocr. Relat. Cancer 17, 273-282 (2010).
91. Cetani, F. et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J. Clin. Endocrinol. Metab. 89, 5583-5591 (2004). (Pubitemid 39518444)
92. Haven, C. J. et al. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin. Endocrinol. (Oxf.) 67, 370-376 (2007). (Pubitemid 47283832)
93. Howell, V. M. et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J. Med. Genet. 40, 657-663 (2003). (Pubitemid 37100697)
94. Shattuck, T. M. et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 349, 1722-1729 (2003). (Pubitemid 37315009)
95. Takahashi, A. et al. SHP2 tyrosine phosphatase converts parafibromin/CDC73 from a tumor suppressor to an oncogenic driver. Mol. Cell 43, 45-56 (2011).
96. Kelly, T. G. et al. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J. Bone Miner. Res. 21, 1666-1671 (2006). (Pubitemid 44484612)
97. Guarnieri, V. et al. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J. Clin. Endocrinol. Metab. 91, 2827-2832 (2006). (Pubitemid 44271719)
98. Frank-Raue, K. et al. CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum. Eur. J. Endocrinol. 165, 477-483 (2011).
99. Cavaco, B. M. et al. Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses. Endocr. Pathol. 22, 44-52 (2011).
100. Barassi, A., Porreca, W., De Pasquale, L., Bastagli, A. & Melzi d'Eril, G. V. Use of intraoperative samples to optimize efficacy of central laboratory parathyroid hormone analyses. Clin. Chem. 53, 535-536 (2007). (Pubitemid 46447955)
101. Wilschut, J. A. et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 141, 1648-1655 (2011).
102. Ladabaum, U. et al. Strategies to identify Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann. Intern. Med. 155, 69-79 (2011).
103. Niramitmahapanya, S. et al. Sensitivity of HRPT2 mutation screening to detect parathyroid carcinoma and atypical parathyroid adenoma of Thai patients. J. Med. Assoc. Thai. 94 (Suppl. 2), S17-S22 (2011).
104. Shaha, A. R. & Shah, J. P. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer 86, 378-380 (1999). (Pubitemid 29347397)
105. Mete, O. & Asa, S. L. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod. Pathol. 12, 1545-1552 (2011).
106. O'Neill, C. J. et al. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. Eur. J. Surg. Oncol. 37, 181-185 (2011).
107. Furlan, J. C., Bedard, Y. C. & Rosen, I. B. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. J. Am. Coll. Surg. 198, 341-348 (2004). (Pubitemid 38283723)
108. Mohebati, A. & Shaha, A. R. Anatomy of thyroid and parathyroid glands and neurovascular relations. Clin. Anat. 25, 19-31 (2012).
109. Kassahun, W. T. & Jonas, S. Focus on parathyroid carcinoma. Int. J. Surg. 9, 13-19 (2011).
110. Wiseman, S. M. et al. Parathyroid carcinoma: a multicenter review of clinicopathologic features and treatment outcomes. Ear Nose Throat J. 83, 491-494 (2004). (Pubitemid 38988570)
111. Mucci-Hennekinne, S. et al. Parathyroid carcinoma: multicenter study of 17 patients [French]. J. Chir. (Paris) 145, 133-137 (2008).
112. Enomoto, K. et al. The surgical strategy and the molecular analysis of patients with parathyroid cancer. World J. Surg. 34, 2604-2610 (2010).
113. O'Neill, C. J. et al. Parathyroid carcinoma encountered after minimally invasive focused parathyroidectomy may not require further radical surgery. World J. Surg. 35, 147-153 (2011).
114. Kebebew, E., Arici, C., Duh, Q. Y. & Clark, O. H. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch. Surg. 136, 878-885 (2001). (Pubitemid 32729547)
115. Harari, A. et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J. Clin. Endocrinol. Metab. 96, 3679-3686 (2011).
116. Witteveen, J. E. et al. Challenges and pitfalls in the management of parathyroid carcinoma: 17-year follow-up of a case and review of the literature. Horm. Cancer 1, 205-214 (2010).
117. Wynne, A. G., van Heerden, J., Carney, J. A. & Fitzpatrick, L. A. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 71, 197-205 (1992).
118. Munson, N. D. et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98, 2378-2384 (2003). (Pubitemid 37466652)
119. Busaidy, N. L. et al. Parathyroid carcinoma: a 22-year experience. Head Neck 26, 716-726 (2004). (Pubitemid 39014637)
120. Clayman, G. L., Gonzalez, H. E., El-Naggar, A. & Vassilopoulou- Sellin, R. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 100, 900-905 (2004). (Pubitemid 38222848)
121. Tochio, M. et al. A case report of 20 lung radiofrequency ablation sessions for 50 lung metastases from parathyroid carcinoma causing hyperparathyroidism. Cardiovasc. Intervent. Radiol. 33, 657-659 (2010).
122. Bradwell, A. R. & Harvey, T. C. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353, 370-373 (1999). (Pubitemid 29088165)
123. Betea, D. et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J. Clin. Endocrinol. Metab. 89, 3413-3420 (2004). (Pubitemid 38951913)
124. Horie, I. et al. First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma. Endocr. J. 57, 287-292 (2010).
125. Lupp, A. et al. Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. Eur. J. Endocrinol. 162, 979-986 (2010).
126. Messa, P., Alfieri, C. & Brezzi, B. Clinical utilization of cinacalcet in hypercalcemic conditions. Expert Opin. Drug Metab. Toxicol. 7, 517-528 (2011).